Cited 4 times in
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2020-12-01T17:13:52Z | - |
dc.date.available | 2020-12-01T17:13:52Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180180 | - |
dc.description.abstract | Background/aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. Results: Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETV-associated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. Conclusion: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934). | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Young Woo | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Si Hyun Bae | - |
dc.contributor.googleauthor | Chang Wook Kim | - |
dc.contributor.googleauthor | Jae Young Jang | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Dong Joon Kim | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Jeong Heo | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.identifier.doi | 10.3350/cmh.2019.0044n | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 32460460 | - |
dc.subject.keyword | Adefovir | - |
dc.subject.keyword | Antiviral drug resistance | - |
dc.subject.keyword | Entecavir | - |
dc.subject.keyword | Lamivudine | - |
dc.subject.keyword | Tenofovir | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 352 | - |
dc.citation.endPage | 363 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.26(3) : 352-363, 2020-07 | - |
dc.identifier.rimsid | 67172 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.